A genetic polymorphism in the fractalkine receptor has been associated with reduced risk for developing coronary artery disease (CAD) [11] and unstable CAD patients have shown increased plasma levels of fractalkine [12]. This evidence concerns the gene CX3CL1 and coronary artery disorder.